Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
Saved in:
| Title: | Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. |
|---|---|
| Authors: | Reijers ILM; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Rawson RV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Colebatch AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.; Department of Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Rozeman EA; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Oncology Department, Royal North Shore Hospital, Sydney, Australia.; Oncology Department, Mater Hospital, Sydney, New South Wales, Australia., van Akkooi ACJ; Department of Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Wouters MW; Department of Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., van Houdt WJ; Department of Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Zuur CL; Department of Head and Neck Surgery, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Otorhinolaryngology, Leiden University Medical Center, Leiden, the Netherlands., Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Ch'ng S; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Klop WMC; Department of Head and Neck Surgery, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Oncology Department, Royal North Shore Hospital, Sydney, Australia.; Oncology Department, Mater Hospital, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Oncology Department, Royal North Shore Hospital, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., van de Wiel BA; Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam.; Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. |
| Source: | JAMA surgery [JAMA Surg] 2022 Apr 01; Vol. 157 (4), pp. 335-342. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589553 Publication Model: Print Cited Medium: Internet ISSN: 2168-6262 (Electronic) Linking ISSN: 21686254 NLM ISO Abbreviation: JAMA Surg Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6262 |
|---|---|
| DOI: | 10.1001/jamasurg.2021.7554 |
